Journal of Clinical Oncology, Vol 26, No 1 (January 1), 2008: pp. 60-65
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.1144
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
Suresh S. Ramalingam,
Suzanne E. Dahlberg,
Corey J. Langer,
Robert Gray,
Chandra P. Belani,
Julie R. Brahmer,
Alan B. Sandler,
Joan H. Schiller,
David H. Johnson
From the Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh; Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Vanderbilt-Ingram Cancer Center, Nashville, TN; and The University of Texas Southwestern Medical Center, Dallas, TX
Corresponding author: Suresh S. Ramalingam, MD, Emory Winship Cancer Institute, 1365 Clifton Rd, Room C-5090, Atlanta, GA 30322; e-mail: suresh.ramalingam{at}emory.edu
Purpose Fit elderly patients with advanced non–small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) improves survival for advanced, nonsquamous NSCLC, as evidenced in Eastern Cooperative Oncology Group (ECOG) 4599. We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients.
Patients and Methods ECOG 4599 randomly assigned patients with advanced nonsquamous NSCLC to PC or to PCB. We analyzed outcome in patients who were at least 70 years of age at the time of study entry. Patient characteristics, efficacy, and toxicity data were compared between PC and PCB for the elderly. Outcomes for elderly and younger patients (< 70 years) treated with PCB were also compared.
Results Among elderly patients (n = 224; 26%), there was a trend towards higher response rate (29% v 17%; P = .067) and progression-free survival (5.9 v 4.9 months; P = .063) with PCB compared with PC, although overall survival (PCB = 11.3 months; PC = 12.1 months; P = .4) was similar. Grade 3 to 5 toxicities occurred in 87% of elderly patients with PCB versus 61% with PC (P < .001), with seven treatment-related deaths in the PCB arm compared with two with PC. Elderly patients had higher incidence of grade 3 to 5 neutropenia, bleeding, and proteinuria with PCB compared with younger patients.
Conclusion In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients.
Presented as a poster at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: From Best Supportive Care to the Combination of Platin-Based Chemotherapy and Targeted Therapies
Cesare Gridelli
JCO 2008 26: 13-15
[Full Text]
Related Correspondence
- Reporting of Subset Analysis: Where Do We Draw the Line?
Sanjay Goel
JCO 2008 26: 2062-2063
[Full Text]
- Improved Survival With Addition of Bevacizumab to Paclitaxel and Carboplatin in Elderly Patients With Non–Small-Cell Lung Cancer
Carl D. Atkins
JCO 2008 26: 2063-2064
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population
Ann. Onc.,
August 28, 2009;
(2009)
mdp360v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist,
May 1, 2009;
14(5):
511 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Horn and A. B. Sandler
Angiogenesis in the Treatment of Non-Small Cell Lung Cancer
Proceedings of the ATS,
April 15, 2009;
6(2):
206 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Ramalingam and F. R. Khuri
The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer
Oncologist,
April 1, 2009;
14(4):
412 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli, P. Maione, and A. Rossi
Chemotherapy and Targeted Therapy for Older Patients with Advanced Non-small Cell Lung Cancer
ASCO Educational Book,
January 1, 2009;
2009(1):
283 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Atkins
Improved Survival With Addition of Bevacizumab to Paclitaxel and Carboplatin in Elderly Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
April 20, 2008;
26(12):
2063 - 2064.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Ramalingam, S. E. Dahlberg, R. Gray, C. J. Langer, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Meaningful Subset Analyses Contribute to Optimal Patient Care
J. Clin. Oncol.,
April 20, 2008;
26(12):
2064 - 2065.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goel
Reporting of Subset Analysis: Where Do We Draw the Line?
J. Clin. Oncol.,
April 20, 2008;
26(12):
2062 - 2063.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Balducci
Journal of Clinical Oncology: The Next 25 Years
J. Clin. Oncol.,
April 1, 2008;
26(10):
e4 - e4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli
Treatment of Advanced Non Small-Cell Lung Cancer in the Elderly: From Best Supportive Care to the Combination of Platin-Based Chemotherapy and Targeted Therapies
J. Clin. Oncol.,
January 1, 2008;
26(1):
13 - 15.
[Full Text]
[PDF]
|
|
|
|
